MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - mnc pharma
- ABBOTT INDIA - SUN PHARMA
ABBOTT INDIA vs SUN PHARMA - Comparison Results
ABBOTT INDIA 
Change
Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
SUN PHARMA
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Current Valuations
| ABBOTT INDIA | SUN PHARMA | ABBOTT INDIA/ SUN PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 38.5 | 24.9 | 154.7% | View Chart |
| P/BV | x | 10.0 | 2.6 | 379.2% | View Chart |
| Dividend Yield | % | 0.7 | 0.5 | 144.1% |
Financials
 ABBOTT INDIA  SUN PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ABBOTT INDIA Mar-18 |
SUN PHARMA Mar-18 |
ABBOTT INDIA/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 6,110 | 701 | 872.2% | |
| Low | Rs | 3,996 | 433 | 922.4% | |
| Sales per share (Unadj.) | Rs | 1,552.2 | 110.4 | 1,405.9% | |
| Earnings per share (Unadj.) | Rs | 188.8 | 11.0 | 1,719.9% | |
| Cash flow per share (Unadj.) | Rs | 196.4 | 17.2 | 1,140.1% | |
| Dividends per share (Unadj.) | Rs | 55.00 | 2.00 | 2,750.0% | |
| Dividend yield (eoy) | % | 1.1 | 0.4 | 308.5% | |
| Book value per share (Unadj.) | Rs | 796.6 | 158.8 | 501.6% | |
| Shares outstanding (eoy) | m | 21.25 | 2,399.26 | 0.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.3 | 5.1 | 63.4% | |
| Avg P/E ratio | x | 26.8 | 51.6 | 51.8% | |
| P/CF ratio (eoy) | x | 25.7 | 32.9 | 78.2% | |
| Price / Book Value ratio | x | 6.3 | 3.6 | 177.7% | |
| Dividend payout | % | 29.1 | 18.2 | 159.9% | |
| Avg Mkt Cap | Rs m | 107,376 | 1,360,021 | 7.9% | |
| No. of employees | `000 | 3.3 | 17.8 | 18.7% | |
| Total wages/salary | Rs m | 3,937 | 53,671 | 7.3% | |
| Avg. sales/employee | Rs Th | 9,929.3 | 14,890.9 | 66.7% | |
| Avg. wages/employee | Rs Th | 1,185.1 | 3,017.1 | 39.3% | |
| Avg. net profit/employee | Rs Th | 1,207.7 | 1,480.6 | 81.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 32,985 | 264,895 | 12.5% | |
| Other income | Rs m | 1,170 | 8,388 | 13.9% | |
| Total revenues | Rs m | 34,155 | 273,282 | 12.5% | |
| Gross profit | Rs m | 5,245 | 56,081 | 9.4% | |
| Depreciation | Rs m | 162 | 14,998 | 1.1% | |
| Interest | Rs m | 38 | 5,176 | 0.7% | |
| Profit before tax | Rs m | 6,215 | 44,295 | 14.0% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -9,505 | 0.0% | |
| Tax | Rs m | 2,203 | 8,452 | 26.1% | |
| Profit after tax | Rs m | 4,012 | 26,338 | 15.2% | |
| Gross profit margin | % | 15.9 | 21.2 | 75.1% | |
| Effective tax rate | % | 35.4 | 19.1 | 185.7% | |
| Net profit margin | % | 12.2 | 9.9 | 122.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 22,655 | 316,359 | 7.2% | |
| Current liabilities | Rs m | 6,681 | 198,643 | 3.4% | |
| Net working cap to sales | % | 48.4 | 44.4 | 109.0% | |
| Current ratio | x | 3.4 | 1.6 | 212.9% | |
| Inventory Days | Days | 65 | 95 | 68.3% | |
| Debtors Days | Days | 29 | 108 | 27.1% | |
| Net fixed assets | Rs m | 835 | 213,178 | 0.4% | |
| Share capital | Rs m | 213 | 2,399 | 8.9% | |
| "Free" reserves | Rs m | 16,715 | 378,606 | 4.4% | |
| Net worth | Rs m | 16,928 | 381,006 | 4.4% | |
| Long term debt | Rs m | 0 | 17,721 | 0.0% | |
| Total assets | Rs m | 24,162 | 643,028 | 3.8% | |
| Interest coverage | x | 163.7 | 9.6 | 1,712.6% | |
| Debt to equity ratio | x | 0 | 0 | 0.0% | |
| Sales to assets ratio | x | 1.4 | 0.4 | 331.4% | |
| Return on assets | % | 16.8 | 4.9 | 342.0% | |
| Return on equity | % | 23.7 | 6.9 | 342.9% | |
| Return on capital | % | 36.9 | 10.0 | 368.5% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 369 | 40,816 | 0.9% | |
| Fx outflow | Rs m | 3,807 | 30,143 | 12.6% | |
| Net fx | Rs m | -3,438 | 10,673 | -32.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,527 | 39,072 | 3.9% | |
| From Investments | Rs m | -2,148 | -33,708 | 6.4% | |
| From Financial Activity | Rs m | -1,024 | -15,393 | 6.7% | |
| Net Cashflow | Rs m | -1,646 | -7,359 | 22.4% | |
Share Holding
| Indian Promoters | % | 0.0 | 63.7 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 7.9 | 5.1 | 154.0% | |
| FIIs | % | 0.1 | 23.0 | 0.4% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.1 | 8.3 | 206.0% | |
| Shareholders | 18,270 | 133,026 | 13.7% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare ABBOTT INDIA With: STERLING BIOTECH SANOFI INDIA ALEMBIC PHARMA ORCHID PHARMA LTD PFIZER
Compare ABBOTT INDIA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)
Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.
Related Views on News
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMost Popular
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)
May 14, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)
May 17, 2019A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.
What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)
May 17, 2019Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.
The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)
May 14, 2019These companies will help the Sensex more than double from current levels.
More|
| |
ABBOTT INDIA SHARE PRICE
May 24, 2019 (Close)
TRACK ABBOTT INDIA
- Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ABBOTT INDIA
ABBOTT INDIA - STRIDES PHARMA SCIENCE COMPARISON
COMPARE ABBOTT INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.